Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO

HAEMONETICS CORP

Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.
Roy Galvin promoted to EVP, Chief Commercial Officer effective immediately; adds Global Hospital business to his remit.
Chan's compensation: $550k base salary, 80% target bonus, $1.6M long-term equity award, plus $350k sign-on bonus.
Chan most recently President of Medtronic's Acute Care & Monitoring business; 25+ years experience.
Stewart Strong continues as President, Global Hospital through April 1, then advisor to CEO for transition.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Frank W. Chan

Executive Vice President, Chief Operating Officer

HAE · HAEMONETICS CORP

Effective: 2025-04-07
Filed: March 3, 2025, 6:59 PM ET

On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frank W. Chan was appointed as Executive Vice President, Chief Operating Officer at HAEMONETICS CORP.

Action: appointed
Role: Executive Vice President, Chief Operating Officer

Exact text from the filing

On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.

View on SEC.gov

HAEMONETICS CORP filing history →

Source: SEC EDGAR

accession 0000313143-25-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.